Abstract 549P
Background
Interstitial pneumonia (IP) or interstitial lung abnormalities (ILA) is a risk factor for drug-induced interstitial lung disease (D-ILD) in immunotherapy. We usually evaluate interstitial pneumonia by CT findings without histopathological findings. We aimed to evaluate whether histopathological findings of the background lung in surgical specimens is correlated with development of D-ILD by immunotherapy in patients with postoperative recurrence.
Methods
Patients who were treated with immunotherapy or immunochemotherapy for first-line treatment of non-small cell lung cancer for postoperative recurrence from April 2017 to February 2023 were included. We retrospectively compared between characteristics of patients with and without D-ILD, including CT findings and histopathological findings of the background lung in surgical specimens.
Results
Among 32 included patients, we evaluated 27 patients whose surgical specimens were available. The median age was 72 years old, and 20 patients (74.1%) were male. Twelve patients (44.4%) had ILA on CT, and five patients (18.5%) had IP with usual interstitial pneumonia (UIP) pattern (two patients with UIP, one patient with probable UIP, and two patients with indeterminate for UIP) on pathology. Five patients (18.5%) developed D-ILD, including two patients with CTCAE grade 1, two patients with grade 2, and one patient with grade 5. Patients with D-ILD were significantly more likely to have ILA on CT than those without D-ILD (5/5[100%] vs. 7/22[31.8%], p<0.01). Although there was no significant difference, two of the patients with D-ILD had UIP pattern on pathology as compared with three of those without D-ILD (2/5[40%] vs. 3/22[13.6%] p=0.22). Four patients had both ILA on CT and UIP pattern on pathology, and two (50%) of these cases developed D-ILD.
Conclusions
In addition to chest CT findings, histopathological findings of the background lung in surgical specimens may be useful as predictors of D-ILD in immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Tanaka: Financial Interests, Personal, Speaker, Consultant, Advisor: Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo; Financial Interests, Personal, Royalties: Bunkodo Co., Ltd., Gakken Inc. N. Katsurada: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K. T. Nagano: Financial Interests, Personal, Invited Speaker: AstraZeneca K.K. M. Yamamoto: Financial Interests, Personal, Speaker, Consultant, Advisor: Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., Daiichi Sankyo, Taiho Pharmaceutical Co., Ltd. M. Tachihara: Financial Interests, Personal, Invited Speaker: Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd, AstraZeneca K.K, MSD K.K., Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Pfizer Japan Inc., Daiichi Sankyo, Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Research Grant: AstraZeneca K.K., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract